Back to top

Analyst Blog

Portola Pharmaceuticals, Inc. (PTLA - Snapshot Report) announced the pricing of its public offering of common stock. The company is looking to issue 6,366,513 shares of its common stock at $23.75 per share.

The underwriters have been granted an option to purchase an additional 954,976 shares, with a 30-day window. The offering is expected to be completed on Oct 22, 2013.

Portola intends to use the funds for further development of its three lead candidates, Betrixaban, PRT2070 and Andexanet alfa (PRT4445).

We note that Portola has been putting in substantial efforts to develop its pipeline. In Oct 2013, the company announced encouraging data from a phase II proof-of-concept study on Andexanet alfa, a Factor Xa inhibitor. The candidate aims to reverse the Factor Xa inhibitor’s anticoagulant activity in patients suffering from uncontrolled bleeding or undergoing emergency surgery.

Results from the study showed that the use of intravenous PRT4445 420 mg bolus dose resulted in around 92% reversal of the anticoagulant activity of Bristol-Myers Squibb Company / Pfizer Inc.’s (BMY - Analyst Report) / (PFE - Analyst Report) Eliquis in two minutes. At the conclusion of a two-hour infusion, PRT4445 resulted in around 91% reversal of the anticoagulant activity of Eliquis. No serious side effects or premature termination of the treatment with PRT4445 has been observed so far in the ongoing safety follow-up of this study.

We remind investors that in Nov 2012, Portola entered into an agreement with Bristol-Myers Squibb and Pfizer to evaluate PRT4445 in combination with Eliquis.

In Oct 2013, the company announced that it has started a phase I/II proof-of-concept study on its oral dual spleen tyrosine kinase and janus kinase inhibitor candidate, PRT2070.

PRT2070 is being evaluated for treating patients suffering from genetically-defined hematologic cancers and patients who have not responded to prior therapy due to relapse or acquired mutations. Furthermore, Betrixaban is being evaluated as a preventive treatment for venous thromboembolism (a type of thrombosis) in acute medically ill patients for up to 35 days.

Portola at present carries a Zacks Rank #3 (Hold). Companies that currently look well positioned include Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
SIGNET JEWE… SIG 116.05 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
TRAVELCENTE… TA 11.66 +4.76%
AIR INDUSTR… AIRI 9.99 +4.15%